1.
SPECIFIC AIMS The CHAVI-ID Operations and Management Support Component, (OMSC) will serve as a resource to the entire CHAVI-ID, providing overall management, coordination and supervision ofthe program. The CHAVI-ID director, Bart Haynes will serve as the leader of the OMSC, and experienced OMSC staff will be responsible for managing and coordinating the entire range of CHAVI-ID activities, monitoring progress and ensuring that the CHAVI-ID Scientific Agenda and Strategic Plan is developed, renewed, and implemented effectively and efficiently.
Specific Aims will include the following.
Aim 1. Provide overall management, coordination and supervision of programs within CHAVI-ID to optimally facilitate HIV-1 vaccine discovery and development.
Aim 2. Ensure timely financial accounting in CHAVI-ID Aim 3. Ensure compliance with all institutional and federal research guidelines. Management of the CHAVI-ID will require remarkably complex and timely coordination of finances, program management, facilities, research and development activities, and investigators across disciplines and institutions. The expertise this group has gained over the past 6 years in CHAVI, will ensure success in the management of CHAVI-ID.

Public Health Relevance

Effective and timely financial and programmatic management are the key to the success for any scientific consortium. Ensuring the management of individual scientific projects, and having the ability to redirect funds in a timely manner as dictated by the science will facilitate HIV-1 vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
1UM1AI100645-01
Application #
8385821
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
Project End
Budget Start
2012-07-15
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$7,471,727
Indirect Cost
$2,530,047
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Richard, Jonathan; Prévost, Jérémie; Baxter, Amy E et al. (2018) Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio 9:
Pardi, Norbert; Hogan, Michael J; Porter, Frederick W et al. (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17:261-279
Bowder, Dane; Hollingsead, Haley; Durst, Kate et al. (2018) Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses. Virology 521:158-168
Madani, Navid; Princiotto, Amy M; Mach, Linh et al. (2018) A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 9:2363
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Dong, Yuanchen; Chen, Shuobing; Zhang, Shijian et al. (2018) Folding DNA into a Lipid-Conjugated Nanobarrel for Controlled Reconstitution of Membrane Proteins. Angew Chem Int Ed Engl 57:2072-2076
Prévost, Jérémie; Richard, Jonathan; Medjahed, Halima et al. (2018) Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol 92:
Prévost, Jérémie; Richard, Jonathan; Ding, Shilei et al. (2018) Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology 515:38-45
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Wu, Helen L; Wiseman, Roger W; Hughes, Colette M et al. (2018) The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. J Immunol 200:49-60

Showing the most recent 10 out of 261 publications